Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE)
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI 545 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI 545; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 4 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 5
B: Arm Label: HCQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxychloroquine (Z0188) | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydroxychloroquine (Z0188); Assigned to Arm(s): HCQ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Abatacept + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Prednisone | Arm Label: Placebo + Prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abatacept + Prednisone, Placebo + Prednisone | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept
D: Arm Label: Sifalimumab 200 milligram (mg); Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 200 mg | Arm Label: Sifalimumab 600 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 600 mg | Arm Label: Sifalimumab 1,200 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 1,200 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Sifalimumab 200 mg; Assigned to Arm(s): Sifalimumab 200 milligram (mg) | Intervention Type: BIOLOGICAL; Name: Sifalimumab 600 mg; Assigned to Arm(s): Sifalimumab 600 mg | Intervention Type: BIOLOGICAL; Name: Sifalimumab 1,200 mg; Assigned to Arm(s): Sifalimumab 1,200 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A